Origami Therapeutics, Inc.

Origami Therapeutics, Inc. is headquartered in San Diego, CA.

Oral drugs to halt neurodegeneration

Neurodegenerative diseases (Alzheimer's, Huntington's, Parkinson's, ALS, and Frontotemporal Dementia) are driven by disease-causing proteins that current treatments don't adequately target.

Origami develops next-generation disease-modifying protein degraders and correctors using its ORICISION drug discovery platform to target and degrade disease-related proteins.

States its approach selectively and efficiently degrades disease-causing proteins while sparing normal forms of the protein, and uses small molecules for broad distribution in the body and ease of manufacture.